Kiromic BioPharma, Inc. reported favorable safety and tolerability, and early efficacy in the fourth patient enrolled in the Company?s Deltacel-01 Phase 1 clinical trial. Deltacel-01 is evaluating Deltacel? (KB-GDT-01), Kiromic?s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies.

Preliminary results of this first patient in the second cohort obtained six weeks after beginning treatment show a favorable safety and tolerability profile, while imaging shows promising early efficacy for the Deltacel? treatment. Scans showed disease stabilization, no new sites of metastatic disease and an 8.5% reduction in the tumor size.

Additionally, this patient experienced quality-of-life benefits from Deltacel treatment including stopping their previous need for prescription pain medication. This patient is being treated at the Beverly Hills Cancer Center (BHCC).